Strs Ohio Buys New Position in Hims & Hers Health, Inc. $HIMS

Key Points

• Strs Ohio has acquired a new stake in Hims & Hers Health, purchasing 49,700 shares valued at approximately $1.47 million. This investment is part of a broader trend of institutional investors increasing their holdings in the company.
• Recent analyst ratings show a mixed outlook for Hims & Hers Health, with two Buy ratings, eight Hold ratings, and three Sell ratings, while the average price target is set at $38.92.
• Hims & Hers Health reported a miss on earnings for the last quarter, with earnings per share of $0.17 compared to an expected $0.18, despite a year-over-year revenue increase of 72.6%.

Strs Ohio bought a new position in shares of Hims & Hers Health, Inc. (NYSE:HIMS - Free Report) during the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 49,700 shares of the company's stock, valued at approximately $1,469,000.

A number of other hedge funds also recently modified their holdings of HIMS. Smartleaf Asset Management LLC boosted its stake in Hims & Hers Health by 15.7% in the first quarter. Smartleaf Asset Management LLC now owns 1,672 shares of the company's stock valued at $49,000 after buying an additional 227 shares in the last quarter. Allworth Financial LP increased its stake in shares of Hims & Hers Health by 20.0% in the first quarter. Allworth Financial LP now owns 2,006 shares of the company's stock valued at $56,000 after buying an additional 334 shares during the period. Signaturefd LLC lifted its position in shares of Hims & Hers Health by 17.7% in the 1st quarter. Signaturefd LLC now owns 2,586 shares of the company's stock worth $76,000 after purchasing an additional 388 shares during the period. Kilter Group LLC raised its stake in Hims & Hers Health by 1.0% during the first quarter. Kilter Group LLC now owns 43,989 shares of the company's stock worth $1,300,000 after buying an additional 450 shares during the last quarter. Finally, Larson Financial Group LLC boosted its position in shares of Hims & Hers Health by 47.7% during the 1st quarter. Larson Financial Group LLC now owns 1,419 shares of the company's stock valued at $42,000 after purchasing an additional 458 shares in the last quarter. Institutional investors own 63.52% of the company's stock.

Hims & Hers Health Stock Up 2.7%

Shares of HIMS stock traded up $1.54 during trading hours on Friday, hitting $57.74. 36,152,647 shares of the company's stock traded hands, compared to its average volume of 27,039,632. The stock's fifty day simple moving average is $50.71 and its two-hundred day simple moving average is $45.66. Hims & Hers Health, Inc. has a 12-month low of $15.73 and a 12-month high of $72.98. The stock has a market cap of $13.05 billion, a price-to-earnings ratio of 72.18, a PEG ratio of 3.80 and a beta of 2.14. The company has a quick ratio of 4.46, a current ratio of 4.98 and a debt-to-equity ratio of 1.72.

Hims & Hers Health (NYSE:HIMS - Get Free Report) last announced its quarterly earnings results on Monday, August 4th. The company reported $0.17 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.18 by ($0.01). Hims & Hers Health had a return on equity of 26.26% and a net margin of 9.63%.The firm had revenue of $544.83 million during the quarter, compared to the consensus estimate of $550.06 million. During the same quarter in the previous year, the firm earned $0.06 EPS. The business's revenue for the quarter was up 72.6% on a year-over-year basis. Hims & Hers Health has set its Q3 2025 guidance at EPS. FY 2025 guidance at EPS. On average, analysts expect that Hims & Hers Health, Inc. will post 0.29 EPS for the current year.

Wall Street Analyst Weigh In

A number of equities research analysts have commented on HIMS shares. Zacks Research cut shares of Hims & Hers Health from a "strong-buy" rating to a "hold" rating in a report on Tuesday, August 19th. UBS Group set a $30.00 price objective on Hims & Hers Health in a research note on Monday, June 23rd. Citigroup reiterated a "sell" rating on shares of Hims & Hers Health in a report on Monday, June 23rd. Truist Financial dropped their target price on shares of Hims & Hers Health from $48.00 to $37.00 and set a "hold" rating on the stock in a research note on Monday, August 18th. Finally, Wall Street Zen downgraded Hims & Hers Health from a "buy" rating to a "hold" rating in a research note on Monday, July 28th. Two analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and three have assigned a Sell rating to the company's stock. According to data from MarketBeat, Hims & Hers Health currently has an average rating of "Reduce" and a consensus target price of $38.92.

Insider Activity at Hims & Hers Health

In other news, CEO Andrew Dudum sold 65,110 shares of the company's stock in a transaction dated Wednesday, September 17th. The shares were sold at an average price of $50.57, for a total transaction of $3,292,612.70. Following the sale, the chief executive officer directly owned 95,315 shares in the company, valued at approximately $4,820,079.55. This represents a 40.59% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Irene Becklund sold 8,410 shares of the business's stock in a transaction that occurred on Wednesday, September 17th. The shares were sold at an average price of $50.50, for a total value of $424,705.00. Following the transaction, the insider owned 1,418 shares of the company's stock, valued at $71,609. This trade represents a 85.57% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 1,535,085 shares of company stock valued at $78,035,921 in the last three months. Corporate insiders own 13.71% of the company's stock.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.